Eledon Pharmaceuticals
ELDN
53 hedge funds and large institutions have $46M invested in Eledon Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 20 increasing their positions, 9 reducing their positions, and 6 closing their positions.
122% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 9
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
8% more funds holding
Funds holding: 49 → 53 (+4)
34% less capital invested
Capital invested by funds: $69.4M → $46M (-$23.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$2.93M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$1.89M |
| 3 |
OPPM
Opus Point Partners Management
New York
|
+$667K |
| 4 |
Renaissance Technologies
New York
|
+$453K |
| 5 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$352K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$8.25M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$6.77M |
| 3 |
KCM
Kingdon Capital Management
New York
|
-$6.13M |
| 4 |
JP Morgan Chase
New York
|
-$1.02M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$922K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
BlackRock
New York
| $2K | – | – | – |
|
|
IA
52
IFP Advisors
Tampa,
Florida
| $2K | +$3.48K | +2 | New |
|
53
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $1 | -$19.2K | -11 | -92% |
|
|
SM
54
Sabby Management
Miami Beach,
Florida
| – | -$6.77M | -4,039 | Closed |
|
|
SKK
55
Shepherd Kaplan Krochuk
Boston,
Massachusetts
| – | -$267K | -159 | Closed |
|
|
OC
56
Oppenheimer & Co
New York
| – | -$141K | -84 | Closed |
|
|
VKH
57
Virtu KCG Holdings
New York
| – | -$119K | -71 | Closed |
|
|
LTFS
58
Ladenburg Thalmann Financial Services
Miami,
Florida
| – | -$3K | -2 | Closed |
|
59
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$3.48K | -2 | Closed |
|
ELDN Hedge Fund Activity: Q4 2015 in Review
53 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q4 2015, worth a combined $46M — down 34% from $69.4M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new ELDN positions and 6 closed out — a net gain of 4 holders — while 20 added to existing stakes and 9 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $2.93M. The largest seller was Novo Holdings A/S, cutting an estimated $8.25M.
- 53 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q4 2015, up from 49 in Q3 2015.
- Funds reported $46M of Eledon Pharmaceuticals stock for Q4 2015, down 34% quarter-over-quarter.
- 10 funds opened new Eledon Pharmaceuticals positions in Q4 2015 and 6 closed out, a net change of +4 holders.
- The largest Eledon Pharmaceuticals buyer in Q4 2015 was BlackRock Fund Advisors, an estimated $2.93M added.
- The largest Eledon Pharmaceuticals seller in Q4 2015 was Novo Holdings A/S, an estimated $8.25M sold.
Based on aggregated 13F filings for Q4 2015.